Market Data graphic

Diversified Industries

You are here

This sector includes a wide-variety of issuers. Included in this group are companies involved in Financial Services, Real Estate, Media, Consumer and Industrial Products.

Diversified industries companies listed on CSE

LeanLife’s products are shelf-stable extractions from flaxseed, a plentiful plant-based source of Omega-3, that give them a significant advantage as a fortified food ingredient.  The products can be used as food additives or as nutraceuticals.  They have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.  LeanLife Health’s industry leading and proprietary Omega-3 product formulations are of the highest quality and contain no cholesterol. Products are available in oil, emulsion and powder forms.

Lophos Holdings Inc. pertains to the cultivation and research of Lophophora williamsii (“peyote cactus”). Additionally, in the long-term, the Company is engaged in the research and development of compounds derived from peyote cactus. The company’s wholly-owned subsidiary, Lophos Pharmaceuticals Corp., is a biosciences company that specializes in peyote cactus cultivation, research, and sale. It is also licensed to possess, produce, sell/provide, send, transport and deliver the controlled substances covered by its Controlled Substances Dealers License (CSDL), namely mescaline, psilocin and psilocybin.

The Fund is authorized to issue an unlimited number of transferable, redeemable units of one class. As the Fund is in the process of terminating, there are currently no redemption rights for unit holders. All units have equal rights and privileges, each of which represents an equal, undivided interest in the net assets of the Fund. Each whole unit is entitled to one vote at all meetings of unit holders and is entitled to participate equally with respect to any and all distributions made by the Fund and distributions upon the termination of the Fund.

The Fund is authorized to issue an unlimited number of transferable, redeemable Class A Units (redemptions are currently suspended). All Class A Units have equal rights and privileges, each of which represents an equal, undivided interest in the net asset value of that class of the Fund. Each whole unit is entitled to one vote at all meetings of unit holders and is entitled to participate equally with respect to any and all distributions made by Class A Units and distributions upon the termination of Class A Units.

ME Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at Medbright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. Medbright’s mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near and mid-term high quality opportunities with strong return potential while maintaining its commitment to governance.

Metalo Manufacturing Inc. (MMI) targets energy intensive sectors and the ownership of downstream production facilities with near-zero CO2 emissions as the driving force behind their modeling. 

Further, MMI is dedicated to the integration of Canadian minerals and value-add through low-cost and clean electricity. 

​MMI is currently a large shareholder in two development projects:

​Pure Fonte Ltée:  MMI continues to advance the measured development of a Pig Iron production plant for steel mills and foundries. This will be unique globally using hydroelectricity as the source of energy, with near-zero CO2 emissions.  Electric Arc Furnace steel mills and iron foundries committed to lowering their CO2 footprint will benefit from this midstream material.  Additionally, the plant has been engineered to be converted to making a green steel if required.

Labrador Sands Inc:  MMI’s second asset is a mineral sands resource near a Canadian seaport with two key and low-cost minerals (feldspars and silica quartz) and their confirmed grades and uses to make glass and ceramic products. The sands will be combined with low-cost and clean electricity to produce a range of energy -intensive products with near-zero CO2 emissions. Production Plants will see a joint venture structure with known operators applied for each production plant including sanitary ware, silicon carbide (made with a biomass), ceramic tiles and tableware, glass products (containers, vials, fiberglass, wool, etc.) and 3D printing. Canada is nearly 100% import dependent on these products.

Collectively, more than $50 million has been invested in assessing and defining market solutions. One asset has a Bankable Feasibility Study and the other a Preliminary Economic Assessment. 

 

MMI’s holding in the two projects is through Grand River Ironsands Incorporated (privately held), where MMI controls 44% of the shares.

Modern Plant Based Foods is a Canadian food company based in Vancouver, British Columbia that offers a portfolio of plant-based products including meat alternatives, dairy-free cheeses, homemade style soups and vegan snacks. The company understands the importance of providing nutritious and sustainable alternatives without sacrificing taste. All products are made free of soy, gluten, nuts and GMOs. Modern Plant-Based Foods' mission is to change the way food is produced and consumed for the benefit of people, animals and the environment by using natural plant-based ingredients.

Moss Genomics Inc. is an emerging consumer genomics company that offers personalized health, anti-aging and wellness offerings guided by genomic, microbiome, and epigenome data. The Company intends to eliminate barriers in healthcare by offering easy-access, at-home, affordable testing paired with easy-to-understand actionable results.

Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

Contact The Team

How can we help you?

Contact the CSE team to find out more.